NCT05673876View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 6, 2023

Primary Completion Date

January 15, 2024

Study Completion Date

January 15, 2024

Conditions
Acute Graft-versus-host Disease
Interventions
DRUG

GDC-8264

GDC-8264 tablets will be administered as per the schedule specified in the respective arms.

Trial Locations (4)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Irving Medical Center, New York

91010

City of Hope National Medical Center, Duarte

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT05673876 - A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) | Biotech Hunter | Biotech Hunter